Multimodal characterization of sustained bioagent release from an epicardial depot for long-term biomaterial incorporation.
This study explores a new method for delivering follistatin-like 1 protein to improve heart function after a heart attack, showing promising results in rats but needing further validation in humans.
Where it sits
this study against the rest of the follistatin-344 corpusSummary and findings
This study investigates the delivery of human follistatin-like 1 protein (FSTL1) using a novel epicardial reservoir system in a rat model of myocardial infarction (MI). Multiple doses of FSTL1 were administered, leading to observed improvements in cardiac performance and structural changes in the heart. The study emphasizes the need for optimized bioagent delivery systems to enhance therapeutic outcomes post-MI.
Abstract
Epicardial delivery of therapies has the potential to prevent adverse remodeling and promote in situ regeneration after myocardial infarction (MI) but further optimization of bioagent dosing and transport to heart muscle is required to maximize their therapeutic potential. Replenishable reservoir systems have enabled localized bioagent delivery to the epicardial surface but therapy transport from these systems is constrained by semipermeable membranes and fibrous capsule formation. Our approach to improved therapy delivery from epicardial reservoir systems is multi-pronged. First, we introduce a membrane-free reservoir system by incorporating a gelatin scaffold into a flexible polymer implant to promote direct integration with the epicardial surface and act as a replenishable depot to encourage myocardial-directed transport. Next, we perform in vitro and ex vivo validations and multi-scale computational simulations to characterize biomaterial, tissue, and organ-level transport of therapy, considering both native tissue architecture, and the effect of blood vessel clearance. As an in vivo use case of our system, we investigated the functional effect of multi-dose regimens of human follistatin-like 1 protein (FSTL1) in a rat model of myocardial infarction (MI). Groups receiving multiple doses of FSTL1 show increased cardiac performance (ejection fraction and fractional shortening), and decreased chamber stiffness 28 days after MI. Multi-dosing increases ventricular wall thickness and reduces infarct size. We demonstrate a dose-dependent increase in blood vessel number and density in the infarct zone. Finally, we establish a computational and experimental framework for patient-specific modeling to optimize implant parameters such as reservoir size and shape, infarct location, and dosing regimens, with a vision for clinical-imaging guided bioagent delivery strategies that can be modified on a per-patient, therapy-specific basis to optimize dosing regimens of various bioagents. This study highlights the potential for integrating personalized computational models with replenishable delivery systems to improve bioagent transport from biomaterials and enhance post-MI therapeutic outcomes.
Background
This paper addresses the challenge of optimizing bioagent delivery to the heart after myocardial infarction (MI), a condition that often leads to adverse remodeling. Previous studies have indicated that localized delivery of therapeutic agents can improve cardiac function, but limitations in transport mechanisms have hindered efficacy. The introduction of a membrane-free reservoir system aims to enhance the integration and delivery of therapies directly to the epicardial surface.
Methods
The study utilized a rat model of myocardial infarction to evaluate the effects of multi-dose regimens of human follistatin-like 1 protein (FSTL1). Specifics regarding the population size, dosing regimen, and duration of treatment were not detailed in the abstract. The primary outcomes measured included cardiac performance metrics and structural changes in the heart.
Results
Groups receiving multiple doses of FSTL1 demonstrated increased cardiac performance, as indicated by improvements in ejection fraction and fractional shortening, along with decreased chamber stiffness 28 days post-MI. Additionally, there was a noted increase in ventricular wall thickness and a reduction in infarct size, alongside a dose-dependent increase in blood vessel number and density in the infarct zone.
Interpretation
While the findings suggest potential benefits of FSTL1 in enhancing cardiac function post-MI, the abstract lacks specific numeric values and statistical significance for these outcomes. The use of a rat model introduces confounding factors that may limit the applicability of results to human patients. The study highlights the importance of personalized computational models for optimizing bioagent delivery, but the clinical relevance remains to be validated in human trials.
Key findings
- Increased cardiac performance (ejection fraction and fractional shortening) 28 days after MI.
- Decreased chamber stiffness 28 days after MI.
- Increased ventricular wall thickness and reduced infarct size with multi-dosing of FSTL1.
- Dose-dependent increase in blood vessel number and density in the infarct zone.
Limitations
- Conducted in a rat model, limiting human applicability.
- Specific numeric data regarding effect sizes not provided.
- Potential confounding factors from the animal model.